Study Title

Optimisation and Safety of an Innovative Nuclear Medicine Treatment: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.

Study Details

Description:

Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.

Sponsor:

Institut Bergonié

Contacts:

Nadège ANIZAN

n.anizan@bordeaux.unicancer.fr

+33556333347

Drug Details

177Lu-PSMA-617
Isotope(s):
    LUTETIUM-177
    Radioisotope: Lu-177
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 6.7 Days
    Decay Mode: BETA, GAMMA
    Energy: Eβeta max 497 keV, Gamma 113-208 keV
    Range: In Tissue: 0.25-2mm
    Decay Daughters: Hf177
    Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
  • LUTETIUM-177
Target(s):
  • PSMA
Chelator: DOTA

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468